Gastric Cancer, Pancreatic Cancer
Conditions
Brief summary
For gastric and pancreatic cancer patients scheduled for primary chemotherapy, we would like to report muscle mass preservation and improvement in quality of life in Chinese characters that received only exercise therapy and high protein supplements at the same time
Detailed description
Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
Interventions
OTHERExercise Therapy, High Protein supplement
patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
Sponsors
Yonsei University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Has provided signed written informed Consent 2. Has a histologically confirmed gastric or pancreatic cancer 3. Has a patient scheduled for chemotherapy - Patients who are scheduled to be treated with TS-1 or Xelox for gastric cancer-adjuvant chemotherapy - Patients scheduled for primary chemotherapy for pancreatic cancer-progressive/transitional diseases
Exclusion criteria
1. Age under 19 or over 90 year of age 2. Eastern Cooperative Oncology Group (ECOG) ≥ 2 3. Patients with severe malnutritional evaluation (PG-SGAC) 4. Any of the following within 3 months prior to study recruitment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack. 5. A person with previous uncontrolled seizures, central nervous system or psychological disorders 6. Have uncontrolled active infection or sepsis 7. Have deep vein thrombosis occurs within 4 weeks prior to the start of test recruitment 8. Severe acute or chronic conditions that may reduce the patient's ability to participate in clinical trials or make it difficult to interpret clinical trial results 9. Pregnant or lactating women. Pregnancy test results are positive in childbearing women 10. Gastrointestinal obstruction, malabsorption syndrome, or diseases that significantly affect digestive functions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of muscle mass between exercise therapy alone and high protein supplement combination groups | 6weeks | Comparison of muscle mass between the exercise therapy single group and the high-protein supplement combination group as assessed by Bioelectrical impedance analsis (BIA) (performed in Week 6) |
| Comparison of muscle variation between exercise therapy alone and high protein supplement combination groups | 6weeks | Comparison of muscle variation between the exercise therapy single group and the high-protein supplement combination group as assessed by Bioelectrical impedance analsis (BIA) (performed in Week 6) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life (QoL) Evaluation (Korean version EORTC QLQ-C30) | 3years | European Organization for Research and Treatment Core Quality of Life Questionnaire (EORTC QLQ-C30) Korean version EORTC QLQ-C30 consists of 30 questions, and total score will be reported. Response options for each EPIC question form a Likert scale, and multi-item scale scores will be summed and transformed linearly to a 0-to-100 scale. The higher the score, the higher the quality of life. Using the QOL questionnaire (EOGRTC QLQ-C30), a total of 3 measurements were taken before chemotherapy and 1 week after chemotherapy. |
| Nutritional status assessment | 3years | Nutritional status assessment for the exercise therapy single group versus the high-protein supplement combination group as assessed by PG-SGA(the Scored Patient-Generated Subjective Global Assessment) |
| Exercise Compliance | 3years | As assessed by compliance for planned exercise (aerobic/strength exercise) adherence rate (%) |
| Overall Survival (OS) | 3years | Overall Survival (OS): The time from the date of first dose and the date of death from any cause. |
| Progression-free survival (PFS) | 3years | Progression-free survival (PFS): To evaluate the treatment effect of High Protein/Placebo Supplement on progression-free survival (PFS) rate at 3years |
| High Protein/Placebo Supplement rate | 3years | As assessed by compliance for planned high protein/placebo supplementation rate (%) |
Countries
South Korea
Outcome results
None listed